We previously advised that the development of CampETEC product was discontinued. To the best of our knowledge, there are no indications of any public takeover offers by third parties in respect of our ordinary shares nor has the Company made any takeover offers in respect of other companies’ shares in the last and current financial year.
Stage not disclosed · ActiveModality: polyclonal antibody (hyper-immune bovine colostrum)
Indications
Traveler's diarrhea(Stage not disclosed)
Status note Lead prescription product candidate based on hyper-immune colostrum technology. In clinical trials (phase not stated in the excerpts); company plans to commence new trials for Traveler's Diarrhea. All other current product candidates besides IMM-124E and IMM-529 are preclinical.
IMM-529
Stage not disclosed · ActiveModality: polyclonal antibody (hyper-immune bovine colostrum)
Target C. difficile
Indications
C. difficile(Stage not disclosed)
Status note Hyper-immune colostrum product candidate for C. difficile; in clinical trials (phase not stated); company plans to commence new trials.
Per-asset detail extracted from the 20-F filed 2025-12-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.